Steven E. Hall's most recent trade in Kymera Therapeutics Inc was a trade of 20,063 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Kymera Therapeutics Inc | Steven E. Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,063 | 20,063 | - | - | Stock Option (Right to Buy) | |
Kymera Therapeutics Inc | Steven E. Hall | Director | 25 Aug 2020 | 2,511,198 | 0 | - | - | Series A Convertible Preferred Stock | ||
Kymera Therapeutics Inc | Steven E. Hall | Director | 25 Aug 2020 | 2,192,249 | 2,192,249 | - | - | Common Stock | ||
Kymera Therapeutics Inc | Steven E. Hall | Director | 25 Aug 2020 | 985,220 | 0 | - | - | Series B Convertible Preferred Stock | ||
Kymera Therapeutics Inc | Steven E. Hall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2020 | 40,127 | 40,127 | - | - | Stock Option (Right to Buy) |